We are a biopharmaceutical company focused on developing therapies for serious or life-threatening diseases. Through our acquisition of SynthRx, Inc. in 2011, we acquired our Membrane Adhesion & Sealant Technology (MAST) platform, which includes proprietary poloxamer-related data and know-how derived from over two decades of clinical, nonclinical and manufacturing experience, and we are leveraging the MAST platform to develop MST-188 for diseases and conditions characterized by microcirculatory insufficiency.
We are a biopharmaceutical company focused on developing therapies for serious or life-threatening diseases. Through our acquisition of SynthRx, Inc. in 2011, we acquired our Membrane Adhesion & Sealant Technology (MAST) platform, which includes proprietary poloxamer-related data and know-how derived from over two decades of clinical, nonclinical and manufacturing experience, and we are leveraging the MAST platform to develop MST-188 for diseases and conditions characterized by microcirculatory insufficiency.
Company Information
- Industry
- Biotechnology
- Company Type
- Privately Held
- Founded
- unknown
- Employee Range
- 11-50
- Revenue Range
- Not available
Location
- Address
- City
- San Diego
- Region
- California
- Postal Code
- Country
- United States